Systematic Review and Meta-analysis of Eculizumab, Inebilizumab, Tocilizumab, and Satralizumab for Neuromyelitis Optica
Chamlagain, R.; shah, S.; Gaire, S.; Paudel, A. K.; Dahal, K.; Kandel, B.; Dhital, R.; Sharma Paudel, B.; Dhakal, S.; Basnet, M.
Show abstract
Neuromyelitis optica is rare, autoimmune-mediated inflammation and demyelination of the central nervous system with a prevalence of 1-2 persons per 100,000 populations. We aim to generate a head-to-head comparison of these drugs with appropriate evidence to guide future trials and treatment guidelines in a patient with recurrent attacks of NMO. We searched the databases like PubMed, MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase for studies published prior to April 2021 using the keywords. Over all 929 patients from 11 different publications were included in the study. Five studies were included for quantitative synthesis. Pooling of studies showed significant mean reduction of ARR in the monoclonal antibody group (-0.26 [-0.35, -0.17], P <0.00001, I2=0%) and the mean difference in EDSS score from baseline in monoclonal antibodies was - 0.23(95% CI [-0.43, -0.03], P=0.02, I2=0%). There was no significant difference in frequency of total reported adverse events between monoclonal antibody and the comparator arm (RR: 1.01 [0.95, 1.07], P=0.74, I2=14%). Our findings, particularly seen from the context of a few RCTs, support the pursuit of larger, multi-center RCTs that evaluate the effectiveness of each of the currently available monoclonal antibodies and better describe their adverse risk profile.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis 93%
- Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland 93%
- Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model 92%
Similar papers in this journal
- Effect of Tranexamic acid for acute spontaneous intracerebral haemorrhage: A systematic review and individual patient data meta-analysis 89%
- Suggestibility in functional neurological disorder: A meta-analysis 89%
- The effect of GLP-1RA exenatide on Idiopathic Intracranial Hypertension: Randomised Clinical Trial 88%
Similar papers in this journal
- Comparative Efficacy and Safety of Tenecteplase and Alteplase in Acute Ischemic Stroke: A Pairwise and Network Meta-analysis of Randomized Controlled Trials 90%
- The effect of galvanic vestibular stimulation on postural balance in Parkinson’s Disease: A systematic review and meta-analysis 89%
- A Prospective Study of Long-Term Outcomes Among Hospitalized COVID-19 Patients with and without Neurological Complications 88%
Similar papers in this journal
- Disability patterns in multiple sclerosis: a meta-analysis on PIRA and RAW in the real world context 93%
- Systematic review and meta-analysis of the association between Epstein-Barr virus, Multiple Sclerosis, and other risk factors 93%
- Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for Multiple Sclerosis 92%
Similar papers in this journal
- Efficacy and safety of erythropoietin for traumatic brain injury: a meta-analysis of randomized controlled trials 90%
- A self-administered, artificial intelligence (AI) platform for cognitive assessment in multiple sclerosis (MS) 90%
- Efficacy and safety of tirofiban following intravenous thrombolysis: A systematic review and meta-analysis of randomized controlled trials 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.